283 related articles for article (PubMed ID: 28089686)
1. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
Iga K; Kiriyama A
J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
[TBL] [Abstract][Full Text] [Related]
2. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
Iga K; Kiriyama A
Biol Pharm Bull; 2017 Dec; 40(12):2024-2037. PubMed ID: 28993551
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
5. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
7. Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
Iga K
J Pharm Sci; 2015 Oct; 104(10):3565-77. PubMed ID: 26099559
[TBL] [Abstract][Full Text] [Related]
8. Structure-Property Relationships and Machine Learning Models for Addressing CYP3A4-Mediated Victim Drug-Drug Interaction Risk in Drug Discovery.
Hu B; Zhou X; Mohutsky MA; Desai PV
Mol Pharm; 2020 Sep; 17(9):3600-3608. PubMed ID: 32794756
[TBL] [Abstract][Full Text] [Related]
9. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
Ohno Y; Hisaka A; Ueno M; Suzuki H
Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
11. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
Mano Y; Sugiyama Y; Ito K
J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
[TBL] [Abstract][Full Text] [Related]
12. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters.
Barth A; Perry CR; Shabbir S; Zamek-Gliszczynski MJ; Thomas S; Dumont EF; Brimhall DB; Nguyen D; Srinivasan M; Swift B
Clin Transl Sci; 2023 Apr; 16(4):647-661. PubMed ID: 36642822
[TBL] [Abstract][Full Text] [Related]
13. Quantitative evaluation of drug-drug interaction potentials by in vivo information- guided prediction approach.
Chen F; Hu ZY; Jia WW; Lu JT; Zhao YS
Curr Drug Metab; 2014; 15(8):761-6. PubMed ID: 25705907
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
Willemin ME; Zannikos P; Mannens G; de Zwart L; Snoeys J
Clin Pharmacokinet; 2022 Aug; 61(8):1115-1128. PubMed ID: 35579824
[TBL] [Abstract][Full Text] [Related]
15. A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.
Tod M; Goutelle S; Bleyzac N; Bourguignon L
Clin Pharmacokinet; 2019 Apr; 58(4):503-523. PubMed ID: 30194612
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
[TBL] [Abstract][Full Text] [Related]
17. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A
Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
Waters NJ
Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
